Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease

Journal of Managed Care Pharmacy

Volumn 13, Issue 4, 2007, Pages 326-336

  Cheng, Judy W ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Acute coronary syndrome; Clopidogrel; Coronary artery disease; Cost effectiveness; Pharmacoeconomics

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SECONDARY PREVENTION; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 34250697109     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.4.326     Document Type: Review

References (40)

1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329-39.
2. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;16;345(7):494-502.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-89.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354 (16):1706-17.
5. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo controlled trial. Lancet. 2005;366(9497):1607-21.
6. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16.
7. Muller C, Buttner HJ, Peterson J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after placement of coronary-artery stent. Circulation. 2000;101:590-93.
8. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation. 2000;102:624-29.
9. Mehta ST, Yusuf S, Peter RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet. 2001;358:527-33.
10. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation. 2001;103(19):2332-35.
11. Waksman T, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation. 2002;106(7):776-78.
12. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-20.
13. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Circulation. 2005; 111 (16):2099-2106.
14. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA. 2005;294(10):1224-32.
15. Plavix prescribing information. Available at: http://products.sanofi-aventis.us/plavix/plavix.html. Accessed July 17, 2006.
16. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295(13):1531-38.
17. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112(19): 2946-50.
18. Shuchman M. Debating the risk of drug-eluting stents. N Engl J Med. 2007;356:325-28.
19. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989-97.
20. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116:797-806.
21. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M Using clopidogrel in non-ST segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health. 2004;7(1):52-60.
22. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction. The Framingham Heart Study Circulation. 1999;100:2054-59.
23. Instituto Nacional de Estadistica. INEbase. Madrid: Instituto Nacional de Estadistica. Available at: http://www.ine.es. Accessed July 21, 2006.
24. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med. 2004;255:562-70.
25. Zethraeus N, Molin T, Henriksson P, et al. Cost of coronary heart disease and stroke: the case of Sweden. J Intern Med. 1999;246:151-59.
26. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J. 2001;22:919-25.
27. Lamy A, Jonsson B, Weintraub S, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil. 2004;11:460-65.
28. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45:838-45.
29. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142:251-59.
30. Badia X, Bueno H, Juanatey JRG, Valentin V, Rubio M. Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev Esp Cardiol. 2005;58(12):1385-95.
31. Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term costeffectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther. 2005;27:100-10.
32. Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006;151:219-27.
33. Ringborg A, Lindgren P, Johsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. Eur J Health Econ. 2005;6:354-62.
34. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrd given for up to one year after percutaneous coronary interventions. J Am Coll Cardiol. 2005;46:761-69.
35. Cowper PA, Udayakumar K, Sketch MH, Peterson ED. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:369-76.
36. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800-06.
37. Karnon J, Brennan A, Pandor A, et al. Modeling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin. 2006;21(1):101-12.
38. American College of Cardiology/American Heart Association. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002. Circulation. 2002;106: 1893-1900.
39. Plavix. Available at: http://www.drugstore.com/pharmacy/prices/ drugprice.asp?ndc=63653117105&trx=lZ5006 Accessed July 17, 2006.
40. Clopidogrel. Available at: http://www.drugstore.com. Accessed January 6, 2007.